EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Nova Eye Medical's Enterprise Value is $20.74 Mil.
Nova Eye Medical's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-3.50 Mil. Therefore, Nova Eye Medical's EV-to-FCF for today is -5.93.
The historical rank and industry rank for Nova Eye Medical's EV-to-FCF or its related term are showing as below:
ELXMF'
s EV-to-FCF Range Over the Past 10 Years
Min: -61.2 Med: -5.73 Max: 2.58
Current: -5.65
During the past 13 years, the highest EV-to-FCF of Nova Eye Medical was 2.58. The lowest was -61.20. And the median was -5.73.
ELXMF's EV-to-FCF is ranked worse than 100% of 419
companies
in the Medical Devices & Instruments industry
Industry Median: 22.67
vs ELXMF: -5.65
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Nova Eye Medical (OTCPK:ELXMF) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Nova Eye Medical's PE Ratio (TTM) for today is calculated as:
Nova Eye Medical's share price for today is $0.01431.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Nova Eye Medical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.017.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Nova Eye Medical EV-to-FCF Related Terms
Nova Eye Medical EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Nova Eye Medical's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Nova Eye Medical's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nova Eye Medical EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nova Eye Medical's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Nova Eye Medical's EV-to-FCF falls into.
Nova Eye Medical's current Enterprise Value is $20.74 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Nova Eye Medical's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-3.50 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nova Eye Medical (ELXMF) has a EV-to-FCF of -5.93 as of Jun. 29, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Nova Eye Medical and its competitors. According to the industry distribution chart, Nova Eye Medical ranks #999999 out of 419 companies in the Medical Devices & Instruments industry.
Is Nova Eye Medical's EV-to-FCF too high?
Nova Eye Medical's current EV-to-FCF is -5.93. Based on the distribution chart, Nova Eye Medical ranks #999999 out of 419 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Nova Eye Medical has a GF Score™ of 55/100, reflecting its overall financial health beyond just this single metric.
How does Nova Eye Medical's EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Nova Eye Medical ranks #999999 out of 419 companies for EV-to-FCF. This places Nova Eye Medical in the lower half of its industry. The industry median EV-to-FCF is 22.67. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 22.67, based on 419 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Nova Eye Medical and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 22.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nova Eye Medical's current EV-to-FCF is -5.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nova Eye Medical stock overvalued right now?
Nova Eye Medical (ELXMF) has a current EV-to-FCF of -5.93. The stock's GF Value™ is $0.02, compared to a current price of $0.01 — trading 28.5% below its estimated fair value. The current EV-to-FCF is -5.93. Nova Eye Medical's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Nova Eye Medical (ELXMF), the current EV-to-FCF is -5.93 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nova Eye Medical (ELXMF) Overvalued in 2026?
Based on GuruFocus' analysis, Nova Eye Medical stock appears to be undervalued.
The current stock price of $0.01 is trading 28.5% below its estimated GF Value™ of $0.02.
Key valuation signals for ELXMF:
EV-to-FCF: -5.93
GF Value™: $0.02 vs. price of $0.01 (28.5% below fair value)
No single metric tells the full story. See the ELXMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nova Eye Medical Ltd develops and sells surgical devices for the treatment of glaucoma, a cause of blindness. In addition, the company is involved in the commercialisation of the subthreshold nano-pulse ophthalmic laser, 2RT, for the treatment of retinal disease via the AlphaRET segment. The company's reportable segments are: Glaucoma Surgical Devices and AlphaRET. The majority of its revenue is generated from the Glaucoma Surgical Devices segment, which is involved in the design, manufacture, marketing, and sale of the iTrack, iTrack Advance, and the Molteno3 glaucoma surgical device. These are all single-use surgical devices. Geographically, the company generates maximum revenue from the United States of America, followed by Europe, the Asia Pacific, Other regions, and Australia.
55GF Score
Get the complete analysis for ELXMF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ELXMF has been successfully added to your 
